Peptide OM-LV20 promotes arteriogenesis induced by femoral artery ligature via the miR-29b-3p/VEGFA axis

• Published in: Atherosclerosis 2024-04, Vol.391, p.117487, Article 117487
• Main Authors: Zhang, Yingxuan, Kang, Zijian, Wang, Jianjun, Liu, Sahua, Liu, Xin, Li, Zhiruo, Li, Yilin, Wang, Yinglei, Fu, Zhe, Li, Jiayi, Huang, Yubing, Ru, Zeqiong, Peng, Ying, Yang, Zhiyu, Wang, Ying, Yang, Xinwang, Luo, Mingying
• Format: Article
• Language: English
• Subjects: Arteriogenesis; Ischemic diseases; miRNA-29b-3p/VEGFA; Peptide; PI3K/AKT/eNOS signaling pathway
• ISSN: 0021-9150; 1879-1484; 1879-1484
• DOI: 10.1016/j.atherosclerosis.2024.117487

Therapeutic arteriogenesis is a promising direction for the treatment of ischemic disease caused by atherosclerosis. However, pharmacological or biological approaches to stimulate functional collateral vessels are not yet available. Identifying new drug targets to promote and explore the underlying mechanisms for therapeutic arteriogenesis is necessary. Peptide OM-LV20 (20 ng/kg) was administered for 7 consecutive days on rat hindlimb ischemia model, collateral vessel growth was assessed by H&E staining, liquid latex perfusion, and specific immunofluorescence. In vitro, we detected the effect of OM-LV20 on human umbilical vein endothelial cells (HUVEC) proliferation and migration. After transfection, we performed quantitative real-time polymerase chain reaction, in situ-hybridization and dual luciferase reporters to assessed effective miRNAs and target genes. The proteins related to downstream signaling pathways were detected by Western blot. OM-LV20 significantly increased visible collateral vessels and endothelial nitric oxide synthase (eNOS), together with enhanced inflammation cytokine and monocytes/macrophage infiltration in collateral vessels. In vitro, we defined a novel microRNA (miR-29b-3p), and its inhibition enhanced proliferation and migration of HUVEC, as well as the expression of vascular endothelial growth factor A (VEGFA). OM-LV20 also promoted migration and proliferation of HUVEC, and VEGFA expression was mediated via inhibition of miR-29b-3p. Furthermore, OM-LV20 influenced the protein levels of VEGFR2 and phosphatidylinositol3-kinase (PI3K)/AKT and eNOS in vitro and invivo. Our data indicated that OM-LV20 enhanced arteriogenesis via the miR-29b-3p/VEGFA/VEGFR2-PI3K/AKT/eNOS axis, and highlighte the application potential of exogenous peptide molecular probes through miRNA, which could promote effective therapeutic arteriogenesis in ischemic conditions. [Display omitted] •OM-LV20 appears to be the first reported amphibian-derived peptide with therapeutic potential of arteriogenesis.•OM-LV20 enhanced collateral vessel growth partially by modulation of miR-29b-3p/VEGFA/VEGFR2-PI3K/AKT/eNOS signaling axis.•Exogenous peptides are important in elucidating the molecular mechanisms and discoverying drug target for arteriogenesis.